Fibrosis Models in Mice and Rats
Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases. To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data. Our platform also includes a clinically relevant NASH model.
Fibrosis models in mice and rats
Related Content
Accelerating SLE Drug Discovery: A Short-Term BM12-Induced Mouse Model for Efficient Drug Screening Systemic lupus erythematosus (SLE) is a chronic...
VIEW RESOURCEInflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease, is a chronic, immune-mediated disorder characterized by persistent inflammation...
VIEW RESOURCE